Literature DB >> 1541548

Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans.

M A Wilson1, T R Kozel.   

Abstract

Encapsulated and nonencapsulated cryptococci differ in their activation of the complement system. Incubation of nonencapsulated cryptococci in normal human serum (NHS) initiates both the classical and alternative pathways. This activation is characterized by an immediate, synchronous activation and binding of C3 to the yeast cells. Encapsulated cryptococci activate only the alternative pathway. This activation is characterized by a delayed (4 to 5 min), asynchronous activation and binding of C3. We examined the properties of antibodies in NHS that mediate immediate, synchronous binding of C3 to nonencapsulated cryptococci and zymosan. Adsorption of NHS with nonencapsulated cryptococci or zymosan produced a 4- to 6-min delay in the kinetics for activation and binding of C3 from the adsorbed serum to each respective yeast cell. This delay was similar to the delay observed when nonencapsulated cryptococci or zymosan was incubated in NHS in which the classical pathway was blocked by chelation of Ca2+. Proteins bound to serum-treated nonencapsulated cryptococci or zymosan were eluted and found to be predominantly immunoglobulin G (IgG), with lesser amounts of IgM. The eluted IgG could restore to adsorbed serum the rapid early kinetics for activation and binding of C3 characteristic of classical pathway initiation. Cross-adsorption showed that there was considerable cross-reactivity between the antibodies which restored rapid, early activation kinetics to NHS adsorbed with zymosan or nonencapsulated cryptococci. Encapsulated cryptococci were unable to adsorb the antibodies from NHS that mediated the rapid, early activation and binding of C3 to zymosan and nonencapsulated cryptococci. The latter results show that occlusion of antigenic sites at the cryptococcal cell wall is a newly recognized property that can be added to the repertoire of biological activities of the cryptococcal capsule.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1541548      PMCID: PMC257550          DOI: 10.1128/iai.60.3.754-761.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

1.  EVIDENCE FOR IMMUNOLOGICAL SPECIFICITY OF THE PROPERDIN SYSTEM; DEMONSTRATION, ISOLATION AND PROPERTIES OF A SERUM FACTOR WHICH INTERACTS WITH ZYMOSAN AND OTHER POLYSACCHARIDES AT 0 DEGREES CENTIGRADE.

Authors:  L BLUM
Journal:  J Immunol       Date:  1964-01       Impact factor: 5.422

2.  Cell-wall glucans of Cryptococcus neoformans Cap 67.

Authors:  P G James; R Cherniak; R G Jones; C A Stortz; E Reiss
Journal:  Carbohydr Res       Date:  1990-04-02       Impact factor: 2.104

3.  Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces.

Authors:  S K Law; N A Lichtenberg; R P Levine
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

4.  Enhancing role of IgG in lysis of rabbit erythrocytes by the alternative pathway of human complement.

Authors:  B Nelson; S Ruddy
Journal:  J Immunol       Date:  1979-05       Impact factor: 5.422

5.  C3 shunt activation in human serum chelated with EGTA.

Authors:  D P Fine; S R Marney; D G Colley; J S Sergent; R M Des Prez
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

6.  Strain variation in phagocytosis of Cryptococcus neoformans: dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3.

Authors:  T R Kozel; G S Pfrommer; A S Guerlain; B A Highison; G J Highison
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

7.  The glucan components of the cell wall of baker's yeast (Saccharomyces cerevisiae) considered in relation to its ultrastructure.

Authors:  J S Bacon; V C Farmer; D Jones; I F Taylor
Journal:  Biochem J       Date:  1969-09       Impact factor: 3.857

8.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

9.  The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan.

Authors:  H A Schenkein; S Ruddy
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

10.  Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

View more
  24 in total

1.  In vivo complement activation and binding of C3 to encapsulated Cryptococcus neoformans.

Authors:  K Truelsen; T Young; T R Kozel
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

2.  Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans.

Authors:  Marcellene A Gates; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

3.  Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans.

Authors:  Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

4.  Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans.

Authors:  Ryan M Kelly; Jianmin Chen; Lauren E Yauch; Stuart M Levitz
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

5.  In vivo role of dendritic cells in a murine model of pulmonary cryptococcosis.

Authors:  Karen L Wozniak; Jatin M Vyas; Stuart M Levitz
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

6.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

7.  Interactions of F1 fractions from different strains of Paracoccidioides brasiliensis with human complement and with human neutrophils.

Authors:  L S Crott; Y M Lucisano-Valim; C L Silva; J E Barbosa
Journal:  Mycopathologia       Date:  1997       Impact factor: 2.574

8.  Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans.

Authors:  A Vecchiarelli; C Retini; A Casadevall; C Monari; D Pietrella; T R Kozel
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Adherence to and damage of endothelial cells by Cryptococcus neoformans in vitro: role of the capsule.

Authors:  A S Ibrahim; S G Filler; M S Alcouloumre; T R Kozel; J E Edwards; M A Ghannoum
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

Review 10.  Polysaccharide antigens of the capsule of Cryptococcus neoformans.

Authors:  R Cherniak; J B Sundstrom
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.